Our sector experience
Baker McKenzie represented Lundbeck in acquiring NASDAQ-listed Longboard Pharmaceuticals for USD 2.6 billion. The acquisition marked a significant milestone in Lundbeck's "Focused Innovator" strategy, which aims at enhancing their portfolio with innovative and complementary products. Under the terms of the merger agreement, Lundbeck commenced and completed a tender offer, followed immediately by a back-end merger, to purchase all outstanding shares of Longboard common stock for USD 60.00 per share in cash for a total equity value of approximately USD 2.6 billion in equity value.
Lundbeck USD 2.6 billion
CASE STUDY
READ MORE
Novonesis EUR 1.5 billion
Advised Novonesis in EUR1.5 billion acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance.
CureVac
Advised CureVac, a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), on restructuring its existing collaboration with GSK.
Galapagos
Advised Galapagos on its separation into two publicly traded entities.
Read More
Read More
Read More
Read More